文献速递前列腺癌

术前PSMA-PET/CT预测前列腺癌根治术后生化持续与早期复发

Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-09-01

本研究纳入213例中高危前列腺癌患者,术前行68Ga或18F-PSMA-PET/CT并接受机器人辅助根治性前列腺切除加扩大盆腔淋巴结清扫。PSMA阳性是术后生化持续(OR 7.1)和早期生化复发(OR 8.1)的显著预测因子,但阴性者仍有20%存在微转移,不应避免淋巴结清扫。

要点

  • 术前PSMA-PET/CT淋巴结阳性显著预测术后生化持续和早期复发。
  • PSMA阴性患者中约20%存在微转移,不应省略扩大盆腔淋巴结清扫。
  • PSMA-PET/CT对pN1的灵敏度29%、特异度84%,需谨慎解读阴性结果。

核心结论

  • 术前PSMA-PET/CT是中高危前列腺癌患者行根治术加扩大淋巴结清扫前咨询的有价值工具,可显著预测术后生化持续和早期生化复发。

研究设计与样本

  • 回顾性评估213例中高危前列腺癌患者,术前接受68Ga或18F-PSMA-PET/CT临床分期,随后行机器人辅助根治性前列腺切除加扩大盆腔淋巴结清扫。
  • 按PSMA-PET/CT淋巴结状态分为PSMA阳性或阴性,并按组织学淋巴结状态分为pN0或pN1。
  • 采用单变量逻辑回归分析评估PSMA阳性对生化持续和早期生化复发的影响。

主要发现

  • PSMA-PET/CT检测pN1的灵敏度29%、特异度84%、阳性预测值35%、阴性预测值80%。
  • 211例中26例(12%)出现生化持续,110例中23例(21%)出现早期生化复发。
  • PSMA阳性是生化持续的显著预测因子(OR 7.1,95%CI 2.9-17.1)和早期生化复发的显著预测因子(OR 8.1,95%CI 2.9-22.6)。

关键数值与推荐

  • 生化持续定义为术后6-12周首次血清PSA≥0.1 ng/mL。
  • 早期生化复发定义为随访12个月内可检测到PSA>0.2 ng/mL。
  • 中高危前列腺癌患者即使术前PSMA-PET/CT阴性,也不应避免扩大盆腔淋巴结清扫,因20%存在微观淋巴结转移。

临床怎么用

  • 术前PSMA-PET/CT淋巴结阳性结果可用于患者咨询,提示术后生化持续和早期复发风险较高。
  • 中高危患者PSMA-PET/CT阴性时仍应行扩大盆腔淋巴结清扫,不应因阴性结果省略清扫。

局限性

  • PSMA-PET/CT检测pN1的灵敏度较低(29%),阴性结果不能排除微转移。
  • 生化持续和早期生化复发的分析样本量不同(分别为211例和110例),早期复发分析样本较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to evaluate the predictive value of lymph nodes (LN) suspicious for metastases on preoperative prostate-specific membrane antigen (PSMA) PET/CT for biochemical persistence (BCP) and early biochemical recurrence (BCR) following robotic-assisted radical prostatectomy (RARP) with extended pelvic LN dissection (ePLND). METHODS: We evaluated 213 patients with intermediate and high-risk prostate cancer (PCa) who underwent clinical staging with preoperative 68Ga- or 18F-PSMA-PET/CT scan and subsequent RARP with ePLND. Patients were grouped as PSMA- or PSMA+ depending on their LN status on PSMA-PET/CT and subdivided according to histological LN status in pN0 or pN1. Diagnostic accuracy of PSMA-PET/CT for the detection of pN1 was evaluated. BCP was defined as a first postoperative serum PSA level ≥0.1 ng/mL 6-12 weeks following RP. Early BCR was defined as detectable PSA > 0.2 ng/mL within 12 months of follow-up. Univariable logistic regression analyses were used to evaluate the effect of PSMA+ on BCP and BCR. RESULTS: Forty patients (19%) were PSMA+. The overall incidence of pN1 was 23%. Sensitivity, specificity, PPV and NPV on a per patient level for the detection of pN1 was 29%, 84%, 35%, and 80% respectively. BCP was observed in 26 of 211 patients (12%) and early BCR in 23 of 110 patients (21%). The presence of PSMA+ was a significant predictor for BCP (OR 7.1, 2.9-17.1 95% CI) and BCR (OR 8.1, 2.9-22.6 95% CI). CONCLUSION: Preoperative PSMA-PET/CT may be a valuable tool for patient counseling for RARP and ePLND as it is a significant predictor for the risk of postoperative BCP and early BCR. We conclude that an ePLND should not be avoided in men with intermediate or high-risk PCa and preoperative negative PSMA-PET/CT, as 20% have microscopic LN metastasis.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Baas DJH, Schilham M, Hermsen R, et al. Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection. Prostate Cancer Prostatic Dis. 2021. PMID: 34471231. doi:10.1038/s41391-021-00452-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。